AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29362260 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention targeting health-promoting policies and practices in junior sporting clubs.
Number of subjects: 0
Study 29362260 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 0
Study 28222815 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Number of subjects: 34
Study 25627448 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV/SOF (8 weeks)
Number of subjects: 1952
Study 25627448 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV/SOF (12 weeks)
Number of subjects: 1952
Study 25627448 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV/SOF (24 weeks)
Number of subjects: 1952
Study 25627448 — intervention group
Group type: COMPARATOR
Intervention: LDV/SOF+RBV (all durations)
Number of subjects: 1952
Study 25627448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained virological response at 12 weeks
Number of subjects: 1952
Study 22914584 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary immunization with recombinant hepatitis B vaccine
Number of subjects: 141
Study 22914584 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary immunization with recombinant hepatitis B vaccine (Group 1, 5 years post-vaccination)
Number of subjects: 141
Study 22914584 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary immunization with recombinant hepatitis B vaccine (Group 2, 10 years post-vaccination)
Number of subjects: 141
Study 22914584 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary immunization with recombinant hepatitis B vaccine (Group 3, 15 years post-vaccination)
Number of subjects: 141
Study 22914584 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of hepatitis B vaccine
Number of subjects: 141
Study 22914584 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of hepatitis B vaccine (administered to children with anti-HBs <10 mIU/mL)
Number of subjects: 141
Study 20683930 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam (1875 mg twice daily for 3 weeks)
Number of subjects: 38
Study 20683930 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to colesevelam, twice daily for 3 weeks)
Number of subjects: 38
Study 20683930 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam
Number of subjects: 38
Study 20683930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 18000709 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg
Number of subjects: 120
Study 18000709 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg plus dexamethasone 8 mg
Number of subjects: 120
Study 18000709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Intralipid)
Number of subjects: 120
Study 18000709 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg/kg combined with dexamethasone 8 mg
Number of subjects: 120
Study 16563558 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m² on days 1 and 8) and Nedaplatin (100 mg/m² on day 1)
Number of subjects: 34
Study 16563558 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Nedaplatin
Number of subjects: 34
Study 14578911 — intervention group
Group type: EXPERIMENTAL
Intervention: BILN 2061, a small molecule NS3 protease inhibitor administered orally for 2 days
Number of subjects: 0
Study 10985991 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 260
Study 10985991 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 260
Study 9011484 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN 3 MU three times a week for six months
Number of subjects: 33
Study 9011484 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN 6 MU three times a week for six months
Number of subjects: 33
Study 9011484 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN 3 MU three times a week for 12 months
Number of subjects: 33
Study 9011484 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN 6 MU three times a week for 12 months
Number of subjects: 33
Study 9011484 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN 3 MU three times a week for up to 18 months
Number of subjects: 33
Study 9011484 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no treatment
Number of subjects: 33
Study 1730124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of radioactive phosphorus (32P)
Number of subjects: 347
Study 1730124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m2)
Number of subjects: 347
Study 1730124 — intervention group
Group type: COMPARATOR
Intervention: 32P
Number of subjects: 347
Study 1730124 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 347
Study 4061965 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (sustained-release form)
Number of subjects: 0
Study 4061965 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide
Number of subjects: 0
Study 29895931 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose (FD) plerixafor 20 mg
Number of subjects: 61
Study 29895931 — intervention group
Group type: COMPARATOR
Intervention: Weight-based (WB) plerixafor 0.24 mg/kg
Number of subjects: 61
Study 29895931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FD and WB groups
Number of subjects: 61
Study 29880728 — intervention group
Group type: EXPERIMENTAL
Intervention: Protaetia brevitarsis seulensis Kolbe, 1886 (PB) extract
Number of subjects: 3
Study 29880728 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxya chinensis sinuosa Mishchenko, 1951 (OC) extract
Number of subjects: 3
Study 29880728 — intervention group
Group type: EXPERIMENTAL
Intervention: Gryllus bimaculatus De Geer, 1773 (GB) extract
Number of subjects: 3
Study 26310871 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOICES (Web-based multimedia education program)
Number of subjects: 234
Study 26310871 — intervention group
Group type: COMPARATOR
Intervention: e-Book (usual care education)
Number of subjects: 234
Study 24359044 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of intravenous dexketoprofen trometamol via slow i.v. infusion (Group I)
Number of subjects: 82
Study 24359044 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg of paracetamol via intravenous infusion (Group II)
Number of subjects: 82
Study 22418981 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary sodium intake
Number of subjects: 1770
Study 22418981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium to calorie intake ratio
Number of subjects: 1770
Study 22418981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium to potassium ratio
Number of subjects: 1770
Study 22418981 — intervention group
Group type: COMPARATOR
Intervention: Prescribed dietary sodium restriction
Number of subjects: 1770
Study 20724934 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EX)
Number of subjects: 108
Study 20724934 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 108
Study 18757354 — intervention group
Group type: EXPERIMENTAL
Intervention: SunWise Policy plus Technical Assistance
Number of subjects: 28
Study 18757354 — intervention group
Group type: COMPARATOR
Intervention: Control (EPA's original SunWise curriculum toolkit)
Number of subjects: 28
Study 18757354 — intervention group
Group type: EXPERIMENTAL
Intervention: SunWise Policy (revised toolkit emphasizing policy)
Number of subjects: 28
Study 15309331 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise or pharmacological stress testing with (99m)Tc-sestamibi, 201Tl or both
Number of subjects: 133
Study 12122552 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g isomalt
Number of subjects: 51
Study 12122552 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g lycasin HBC
Number of subjects: 51
Study 12122552 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g lycasin HBC
Number of subjects: 51
Study 12122552 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g isomalt
Number of subjects: 51
Study 10380982 — intervention group
Group type: EXPERIMENTAL
Intervention: Single feature conditions (color or orientation)
Number of subjects: 0
Study 10380982 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunction targets (both color and orientation)
Number of subjects: 0
Study 8531615 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-parameter nonlinear model
Number of subjects: 16
Study 8531615 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-parameter nonlinear model
Number of subjects: 16
Study 8531615 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear (P.t) model
Number of subjects: 16
Study 8531615 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear (P) model
Number of subjects: 16
Study 8531615 — intervention group
Group type: EXPERIMENTAL
Intervention: Exponential model
Number of subjects: 16
Study 8531615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory threshold for long-term exercise (LTE Tvent)
Number of subjects: 16
Study 1693733 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER tablets 10 mg once daily (n = 50)
Number of subjects: 102
Study 1693733 — intervention group
Group type: COMPARATOR
Intervention: Plain tablets 5 mg twice daily (n = 52)
Number of subjects: 102
Study 582722 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. cefazedone 500 mg
Number of subjects: 10
Study 582722 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. cefazedone 1000 mg
Number of subjects: 10
Study 582722 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. cefazedone 500 mg
Number of subjects: 10
Study 582722 — intervention group
Group type: COMPARATOR
Intervention: cefazolin 1000 mg
Number of subjects: 10
Study 582722 — intervention group
Group type: COMPARATOR
Intervention: cefazolin 500 mg
Number of subjects: 10
Study 30413390 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter removal on postoperative day 3 (POD 3)
Number of subjects: 146
Study 30413390 — intervention group
Group type: COMPARATOR
Intervention: Catheter removal on postoperative day 5 (POD 5)
Number of subjects: 146
Study 31113763 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access
Number of subjects: 1388
Study 31113763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 1388
Study 31113763 — intervention group
Group type: COMPARATOR
Intervention: Standard guidance
Number of subjects: 1388
Study 31113763 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral access
Number of subjects: 1388
Study 29167518 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased theta activity during menstrual phase
Number of subjects: 46
Study 29167518 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased theta activity during periovulatory phase
Number of subjects: 46
Study 29167518 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations between theta activity and psychological measures
Number of subjects: 46
Study 26690199 — intervention group
Group type: EXPERIMENTAL
Intervention: rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF)
Number of subjects: 151
Study 26690199 — intervention group
Group type: COMPARATOR
Intervention: efavirenz (EFV)/FTC/TDF
Number of subjects: 151
Study 26690199 — intervention group
Group type: EXPERIMENTAL
Intervention: baseline HIV-1 RNA >100,000 copies/mL
Number of subjects: 151
Study 26690199 — intervention group
Group type: COMPARATOR
Intervention: baseline samples from control subjects
Number of subjects: 151
Study 26690199 — intervention group
Group type: EXPERIMENTAL
Intervention: deep sequencing
Number of subjects: 151
Study 24124672 — intervention group
Group type: EXPERIMENTAL
Intervention: CTEPH group
Number of subjects: 116
Study 24124672 — intervention group
Group type: EXPERIMENTAL
Intervention: CTEPH and CPE groups
Number of subjects: 116
Study 24124672 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP
Number of subjects: 116
Study 24124672 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular internal diameter and VO2/kg
Number of subjects: 116
Study 21147813 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training according to Yoga In Daily Life(®) system
Number of subjects: 32
Study 21147813 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 32
Study 18310964 — intervention group
Group type: EXPERIMENTAL
Intervention: delapril 30 mg/manidipine 10 mg combination
Number of subjects: 88
Study 18310964 — intervention group
Group type: COMPARATOR
Intervention: olmesartan 20 mg/HCTZ 12.5 mg combination
Number of subjects: 88
Study 17518172 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of remifentanil plus morphine and nonsteroidal anti-inflammatory drugs
Number of subjects: 29
Study 17518172 — intervention group
Group type: COMPARATOR
Intervention: Bolus doses of fentanyl
Number of subjects: 29
Study 12920414 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (TRZ)
Number of subjects: 16
Study 12920414 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 16
Study 10998766 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity program
Number of subjects: 235
Study 10998766 — intervention group
Group type: COMPARATOR
Intervention: Structured exercise program
Number of subjects: 235
Study 9384327 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermagraft, a tissue-engineered living human dermal tissue; specific dosage and duration not mentioned.
Number of subjects: 0
Study 1562861 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ECT
Number of subjects: 0
Study 1562861 — intervention group
Group type: COMPARATOR
Intervention: Simulated ECT
Number of subjects: 0
Study 3934930 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 60
Study 3934930 — intervention group
Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 60
Study 30549486 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (antidepressant)
Number of subjects: 174
Study 30549486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 26808489 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 208
Study 26808489 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 208
Study 24781568 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS target of 35 (low group)
Number of subjects: 125
Study 24781568 — intervention group
Group type: COMPARATOR
Intervention: SE target of 50 (high group)
Number of subjects: 125
Study 22329472 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (1998 mg/day)
Number of subjects: 33
Study 22329472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 20213210 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey responses from surgeons regarding adherence to evidence-based surgical practices.
Number of subjects: 110
Study 20213210 — intervention group
Group type: COMPARATOR
Intervention: Survey responses from surgeons at different institutions and experience levels.
Number of subjects: 110
Study 20213210 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to 13 questions involving different aspects of gastrointestinal surgery.
Number of subjects: 110
Study 17989696 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy, started at a dose of 5 parts per million (p.p.m.), maximal dose 20 p.p.m.
Number of subjects: 65
Study 17989696 — intervention group
Group type: COMPARATOR
Intervention: Control group (inhaled oxygen placebo only)
Number of subjects: 65
Study 17989696 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy
Number of subjects: 65
Study 16046440 — intervention group
Group type: EXPERIMENTAL
Intervention: Flocculant-disinfectant
Number of subjects: 6650
Study 16046440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite
Number of subjects: 6650
Study 16046440 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 6650
Study 16046440 — intervention group
Group type: COMPARATOR
Intervention: Control and Sodium hypochlorite
Number of subjects: 6650
Study 16046440 — intervention group
Group type: EXPERIMENTAL
Intervention: Flocculant-disinfectant and Sodium hypochlorite
Number of subjects: 6650
Study 12351491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.i.d. for 3 days
Number of subjects: 7
Study 12351491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 12351491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride and Placebo
Number of subjects: 7
Study 10705707 — intervention group
Group type: EXPERIMENTAL
Intervention: propionyl‐L‐carnitine
Number of subjects: 18
Study 10705707 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 9166505 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg oral granisetron HCI twice a day for 7 days
Number of subjects: 230
Study 9166505 — intervention group
Group type: COMPARATOR
Intervention: 10 mg oral prochlorperazine sustained-release capsules twice a day for 7 days
Number of subjects: 230
Study 1901104 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous medium-chain triglycerides (MCT)
Number of subjects: 18
Study 1901104 — intervention group
Group type: COMPARATOR
Intervention: Intravenous long-chain triglycerides (LCT)
Number of subjects: 18
Study 7048918 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 93
Study 7048918 — intervention group
Group type: COMPARATOR
Intervention: Adenine arabinoside (ara-A)
Number of subjects: 93
Study 30922814 — intervention group
Group type: EXPERIMENTAL
Intervention: CNSA-001 (sepiapterin) 2.5–80 mg/kg
Number of subjects: 83
Study 30922814 — intervention group
Group type: EXPERIMENTAL
Intervention: CNSA-001 (sepiapterin)
Number of subjects: 83
Study 30922814 — intervention group
Group type: EXPERIMENTAL
Intervention: CNSA-001 (sepiapterin) 5, 20 or 60 mg/kg (repeat daily dosing)
Number of subjects: 83
Study 27928880 — intervention group
Group type: EXPERIMENTAL
Intervention: InterTAK Diagnostic Score
Number of subjects: 218
Study 25872619 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo control (APC)
Number of subjects: 0
Study 25872619 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training program
Number of subjects: 0
Study 24423077 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured GFR using Iohexol
Number of subjects: 1300
Study 24423077 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated GFR (eGFR) based on serum creatinine and/or cystatin C
Number of subjects: 1300
Study 24423077 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary albumin-to-creatinine ratio
Number of subjects: 1300
Study 23444761 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 microg every four hours, up to three doses)
Number of subjects: 40
Study 23444761 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg every four hours, up to three doses)
Number of subjects: 40
Study 23444761 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (600 microg primary dosage)
Number of subjects: 40
Study 23444761 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (600 microg primary dosage) and continuation of oral dose
Number of subjects: 40
Study 19006526 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized weekly exercise for 13 weeks
Number of subjects: 31
Study 19006526 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study 17979896 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 1296
Study 17979896 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 1296
Study 15343235 — intervention group
Group type: EXPERIMENTAL
Intervention: GHQ‐12 screening tool
Number of subjects: 222
Study 15343235 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cutoff score of GHQ‐12
Number of subjects: 222
Study 11591185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (20 mg, inhaled twice a day; 5.2 mg, intranasally twice a day)
Number of subjects: 32
Study 11591185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11591185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 32
Study 9491869 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized instruction in pelvic muscle exercise
Number of subjects: 46
Study 9491869 — intervention group
Group type: COMPARATOR
Intervention: Routine care with no systematic pelvic muscle exercise instruction (Control)
Number of subjects: 46
Study 8149771 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training program
Number of subjects: 0
Study 8149771 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity training program
Number of subjects: 0
Study 3346988 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care (SC) group
Number of subjects: 0
Study 3346988 — intervention group
Group type: COMPARATOR
Intervention: Referred care (RC) control group
Number of subjects: 0
Study 31867713 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 1591
Study 31867713 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 1591
Study 29576514 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer staff assistance
Number of subjects: 10000
Study 29576514 — intervention group
Group type: COMPARATOR
Intervention: Bin tops
Number of subjects: 10000
Study 29576514 — intervention group
Group type: COMPARATOR
Intervention: Sample 3D items with bin tops
Number of subjects: 10000
Study 26093975 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 429
Study 26431299 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold diode‐laser micropulse (SDM)
Number of subjects: 62
Study 26431299 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose verteporfin photodynamic therapy (hdPDT)
Number of subjects: 62
Study 26431299 — intervention group
Group type: COMPARATOR
Intervention: Control group (CSC observation)
Number of subjects: 62
Study 24016498 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 2331
Study 24016498 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2331
Study 20956265 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle reconstruction
Number of subjects: 32